Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Depreciation & Amortization (CF): 2016-2025

Historic Depreciation & Amortization (CF) for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $17,000.

  • Tg Therapeutics' Depreciation & Amortization (CF) rose 54.55% to $17,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $47,000, marking a year-over-year decrease of 51.55%. This contributed to the annual value of $68,000 for FY2024, which is 67.77% down from last year.
  • As of Q3 2025, Tg Therapeutics' Depreciation & Amortization (CF) stood at $17,000, which was up 30.77% from $13,000 recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Depreciation & Amortization (CF) registered a high of $80,000 during Q4 2021, and its lowest value of $8,000 during Q1 2025.
  • Its 3-year average for Depreciation & Amortization (CF) is $28,818, with a median of $19,000 in 2024.
  • Per our database at Business Quant, Tg Therapeutics' Depreciation & Amortization (CF) skyrocketed by 97.06% in 2021 and then plummeted by 84.93% in 2024.
  • Over the past 5 years, Tg Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $80,000 in 2021, then declined by 8.75% to $73,000 in 2022, then slumped by 47.95% to $38,000 in 2023, then plummeted by 76.32% to $9,000 in 2024, then skyrocketed by 54.55% to $17,000 in 2025.
  • Its Depreciation & Amortization (CF) was $17,000 in Q3 2025, compared to $13,000 in Q2 2025 and $8,000 in Q1 2025.